Zymeworks Inc., a clinical-stage biotechnology company, has provided an update on its strategic priorities for 2024 and 2025, emphasizing the advancement of its R&D pipeline and the development of novel biotherapeutics for difficult-to-treat diseases. The company is well-positioned with cash resources of approximately $455 million as of December 31, 2023, and an expected cash runway into the second half of 2027.
Key highlights include:
- Top-line data readout from the Phase 3 trial evaluating zanidatamab in HER2-positive gastroesophageal adenocarcinoma (GEA), expected in 2024.
- Regulatory reviews for zanidatamab in second-line biliary tract cancers (BTC) in the United States and China, in collaboration with Jazz Pharmaceuticals and BeiGene.
- Investigational New Drug (IND) applications and first-in-human (FIH) studies for ZW171 and ZW191 candidates in 2024, and ZW220 and ZW251 in 2025.
Kenneth Galbraith, Chair and CEO of Zymeworks, highlighted the company's achievements in 2023, including the nomination of new preclinical product candidates and the strengthening of the board of directors. The company's '5 by 5' portfolio and ADVANCE R&D strategy are central to its goal of advancing a broad and differentiated product pipeline.
Zymeworks also provided an update on its financial guidance, with unaudited cash resources of approximately $455 million as of December 31, 2023. The company expects to fund its R&D programs and business operations into the second half of 2027, supported by a recent private placement.
Looking ahead, Zymeworks plans to continue its collaboration agreements with Jazz Pharmaceuticals and BeiGene, focusing on the commercialization of zanidatamab and the expansion of its product pipeline. The company also aims to advance its scientific strategy, targeting five new INDs by 2026, and to explore new opportunities for development collaborations and partnerships.
Zymeworks will present at the J.P. Morgan 42nd Annual Healthcare Conference on January 11, 2024, providing further insights into its strategic priorities and outlook for the coming years.
